IO

RENI - Resilient Energy Inc. Announces Major Breakthrough: Recent Acquisition, Challenger Aerospace & Defense, Inc., Secures Order for Cutting-Edge Aerial Surveillance System

Retrieved on: 
Mittwoch, Mai 1, 2024
MMS, USD, Acceleration, Aerospace, Intelligence, Government, Research report, IO, GPU, Defense, 3D printing

HOUSTON, May 1, 2024 /PRNewswire/ -- Resilient Energy, Inc. (OTC Markets: RENI) ("RENI" or "the Company") is pleased to announce an inaugural order received by its recently acquired powerhouse, Challenger Aerospace & Defense, Inc ("CADI"). RENI anticipates immediate revenues of approximately $552,000, bolstered by the received purchase orders. This milestone marks RENI's bold entry into the dynamic global airborne surveillance market, which is expected to grow to over $9.2 billion by 2033.

Key Points: 
  • HOUSTON, May 1, 2024 /PRNewswire/ -- Resilient Energy, Inc. (OTC Markets: RENI) ("RENI" or "the Company") is pleased to announce an inaugural order received by its recently acquired powerhouse, Challenger Aerospace & Defense, Inc ("CADI").
  • RENI anticipates immediate revenues of approximately $552,000, bolstered by the received purchase orders.
  • This milestone marks RENI's bold entry into the dynamic global airborne surveillance market, which is expected to grow to over $9.2 billion by 2033.
  • Mr. Jon Bianco, CEO of Resilient Energy, Inc., hailed the recent influx of orders, stating, "Challenger Aerospace & Defense, Inc. sets the bar high, and we eagerly rise to the challenge.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Montag, April 22, 2024
CD73, Research, IND, Form, IO, AACR, Fungemia, Immunotherapy, Congress, Annual report, ESMO, Janssen, Tax, DFC, Therapy, SAN, Tavarua, Safety, Annual general meeting, SITC, Collaboration, Caspofungin, Society, Workplace, European, The San Diego Union-Tribune, CDTX, Patient, Bank statement, Pharmaceutical industry

“2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • “2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • Presented at IDWeek 2023: In October 2023, Cidara presented new preclinical and clinical data on Novel Cloudbreak Influenza Drug-Fc Conjugate CD388 at IDWeek 2023.
  • Net loss for the three months ended December 31, 2023 was $3.2 million, compared to a net loss of $13.6 million for the three months ended December 31, 2022.
  • Net loss for the full year ended December 31, 2023 was $22.9 million, compared to a net loss of $33.6 million for the year ended December 31, 2022.

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Retrieved on: 
Montag, April 15, 2024
University, Cancer, Commercial, Kite Pharma, Jazz Pharmaceuticals, Vaccine, Therapy, SVP, Patient, Doctor of Pharmacy, IO, Trade, Amgen, Pharmaceutical industry

Ms. Shamsaei joins the company’s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States.

Key Points: 
  • Ms. Shamsaei joins the company’s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States.
  • “Marjan’s extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercial readiness phase for IO102-IO103,” said Dr. Zocca.
  • “We’re thrilled to welcome Marjan to the IO Biotech team as we continue to expand our pipeline with product candidates in multiple cancer indications where the T-Win platform may prove highly effective.”
    Dr. Shamsaei added, “It is an honor to join IO Biotech’s team during this exciting growth phase in the company.
  • Prior to this role, she served in leadership roles at Five Prime Therapeutics (acquired by Amgen), Genentech, Jazz Pharmaceuticals and SUGEN/Pharmacia (acquired by Pfizer).

BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes

Retrieved on: 
Dienstag, April 30, 2024
Science, Biotechnology, Research, Oncology, Health, Artificial Intelligence, Technology, Genetics, Patient, Machine learning, Immunotherapy, MD, Doctor of Philosophy, IO, Toxicity, Multimedia, Biomarker, Flow cytometry

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • BostonGene’s revolutionary immunoprofiling incorporates flow cytometry and RNA-sequencing to track changes in the peripheral blood, which will be correlated with genetic variations from germline DNA testing to uncover blood-based signatures with immunotherapy response, resistance and toxicity.
  • “PICI’s mission-focused collaboration with BostonGene is a significant step toward unlocking the potential of blood-based biomarkers to advance personalized immunotherapy,” said Tarak Mody, PhD, Chief Business Officer at PICI.
  • Together, we're pioneering the search for blood-based biomarkers," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Alentis Appoints Alberto Toso Chief Scientific Officer

Retrieved on: 
Montag, April 29, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Management, Cancer, Nature, CLDN1, ETH, Doctor of Philosophy, Roche, Toso, Prostate cancer, Pembrolizumab, CSO, IO, Multimedia, Head, Drug development, Cell Reports, Spacecraft, Pharmaceutical industry

Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately.

Key Points: 
  • Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately.
  • Alberto joined Alentis in 2021 as Head of Oncology.
  • View the full release here: https://www.businesswire.com/news/home/20240429009341/en/
    Alberto Toso, Chief Scientific Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)
    “Alberto has been instrumental in rapidly advancing and expanding our oncology pipeline,” said Roberto Iacone, Chief Executive Officer of Alentis.
  • As a postdoc at the Institute of Oncology Research in Bellinzona, Switzerland, Alberto developed and characterized mouse models for prostate cancer.

HireVue Science Team Showcases Latest Research on Ethical AI and Performance Prediction at SIOP Annual Conference

Retrieved on: 
Mittwoch, April 10, 2024
Society, Walmart, Publication, HR, Psychology, Conference, Research, Artificial intelligence, SIOP, Data science, Human, Charter Communications, Eye, IO, Fairness, Algorithmic bias, Algorithm

SALT LAKE CITY, April 10, 2024 (GLOBE NEWSWIRE) -- HireVue, the pioneer and global leader in Human Potential Intelligence, today announced its latest research publications and contributions to industrial organizational psychology, data science, and talent assessment. The team will present 23 sessions at the Society for Industrial Organizational Psychology’s (SIOP) Annual Conference, and principal IO consultant, Dr. Carter Gibson, will receive the coveted award for Distinguished Early Career Contribution.

Key Points: 
  • The team will present 23 sessions at the Society for Industrial Organizational Psychology’s (SIOP) Annual Conference, and principal IO consultant, Dr. Carter Gibson, will receive the coveted award for Distinguished Early Career Contribution.
  • The HireVue Science Team continues to advance both theory and practice at the intersection of performance prediction and the ethical creation of artificial intelligence.
  • This year’s SIOP presentations emphasize how to ethically use AI to score video interviews, game-based assessments, and job simulations while delivering more predictive hiring than if humans made the decisions alone.
  • “Carter continually exemplifies the scientist-practitioner model through his commitment to improving how companies identify and select high-potential talent,” said Dr. Mike Hudy, Chief Science Officer at HireVue.

BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients

Retrieved on: 
Dienstag, April 16, 2024
Research, Technology, Medical Devices, Genetics, Health Technology, Biotechnology, Health, Science, Oncology, Artificial Intelligence, NEC, Cancer, Immunotherapy, Recurrence, MD, Tumor microenvironment, Saga University, ICIS, ICI, Patient, IO, Toxicity, Multimedia, Standard of care, Biomarker, EGFR, NSCLC, TME, Lung cancer, Pharmaceutical industry

Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization.

Key Points: 
  • Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization.
  • However, combination therapy with ICIs and anti-angiogenic agents has shown promise in EGFR-positive lung cancer.
  • By partnering with BostonGene, we aim to uncover novel biomarkers to revolutionize how we approach immunotherapy treatment in EGFR-positive lung cancer, ultimately improving patient outcomes,” said Dr. Naoko Aragane, Professor of Saga University.
  • “Our collaboration with Saga University underscores our dedication to advancing the standard of care in Japan by bringing novel technologies to the region.

Fiat infrastructure Leader Banxa join forces with Venom foundation in offering Venom-supported tokens access to its global Fiat rails

Retrieved on: 
Dienstag, April 16, 2024
Kucoin, Blockchain, Defi, Fiat, IO, Cryptocurrency

DUBAI, UAE, April 16, 2024 /PRNewswire/ -- Fiat infrastructure leader Banxa will add Venom-supported tokens to its Fiat onramp infrastructure, used by leading crypto exchanges such as Okx, Kucoin, Gate.IO, Bybit and others.

Key Points: 
  • DUBAI, UAE, April 16, 2024 /PRNewswire/ -- Fiat infrastructure leader Banxa will add Venom-supported tokens to its Fiat onramp infrastructure, used by leading crypto exchanges such as Okx, Kucoin, Gate.IO, Bybit and others.
  • Integrating Venom foundation network to the Banxa Fiat rails will further boost the business value Venom presents to its Dapps and token developers community.
  • The companies will launch and offer this value proposition to the Venom TokenForge hackathon participants this week in Dubai.
  • Commenting on the cooperation, Venom foundation CEO, Christopher Louis Tsu said: "We are excited to add even more business value to our token partners by offering global Fiat access to users with Banxa onramp network.

SITC and the NCI Announce Fourth Year of Collaboration with the New AI in IO: Computational Immuno-oncology Webinar Series

Retrieved on: 
Freitag, April 12, 2024
Medical school, Immunotherapy, Society, Bangladesh Technical Education Board, Chairperson, AI, DRSN, Series, MD, Doctor of Philosophy, National Cancer Institute, Research, Artificial intelligence, Intelligence, Computation, Science, NCI, SITC, Big data, IO, UPMC Hillman Cancer Center, Knowledge, Chair

MILWAUKEE, April 12, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce their collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, on the fourth Computational Immuno-oncology Webinar Series. This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO). As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".

Key Points: 
  • This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO).
  • As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".
  • This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO).
  • As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Retrieved on: 
Freitag, April 5, 2024
External, Medical biology, IO, Employment, Survival, Pfizer, Business development, Cancer, Engineering, Doctor of Philosophy, Eli Lilly and Company, Kadmon Corporation, Vaccine, Lead, Pharmaceutical industry

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.

Key Points: 
  • NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.
  • Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships.
  • Dr. Miyara will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the company’s executive team, effective immediately.
  • “We are very excited to welcome Faiçal to IO Biotech,” said Dr. Zocca.